22.77
-0.27(-1.17%)
Currency In USD
| Previous Close | 23.04 |
| Open | 22.55 |
| Day High | 23.52 |
| Day Low | 22.46 |
| 52-Week High | 29.27 |
| 52-Week Low | 6.2 |
| Volume | 17,410 |
| Average Volume | 81,275 |
| Market Cap | 251.45M |
| PE | -2.91 |
| EPS | -7.83 |
| Moving Average 50 Days | 24.6 |
| Moving Average 200 Days | 18.04 |
| Change | -0.27 |
If you invested $1000 in Palvella Therapeutics, Inc. (PVLA) since IPO date, it would be worth $1,339.41 as of May 09, 2025 at a share price of $22.77. Whereas If you bought $1000 worth of Palvella Therapeutics, Inc. (PVLA) shares 0 years ago, it would be worth $1,339.41 as of May 09, 2025 at a share price of $22.77.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025
GlobeNewswire Inc.
Yesterday at 11:30 AM GMT
WAYNE, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare
Palvella Therapeutics to Ring the Nasdaq Opening Bell on May 12, 2025
GlobeNewswire Inc.
May 05, 2025 11:30 AM GMT
WAYNE, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering fr
Palvella Therapeutics Announces Abstract Highlighting the Estimated Diagnosed Prevalence and Annual Incidence of Lymphatic Malformations in the U.S. Accepted for Poster Presentation at the 82nd Annual Meeting of the Society for Investigative Dermatology
GlobeNewswire Inc.
Apr 23, 2025 8:15 PM GMT
Quantitative analysis of medical claims indicates an estimated 44,553 to 92,967 diagnosed U.S. patients with lymphatic malformations (LMs) with cutaneous involvement Estimates of annual incidence of LMs with cutaneous involvement to be highlighted in